BioCryst Pharmaceuticals | BCRX - Cost Of Sales


BioCryst Pharmaceuticals reported $9.52M in Cost of Sales for its fiscal quarter ending in December of 2025.





Cost Of Sales Change Date
Alnylam Pharmaceuticals USD 267.72M 67.57M Dec/2025
BioCryst Pharmaceuticals USD 9.52M 7.34M Dec/2025
Chugai Pharma JPY 87.56B 12.68B Dec/2025
Daiichi Sankyo JPY 118.28B 37.7B Dec/2025
Gilead Sciences USD 1.62B 50M Dec/2025
GlaxoSmithKline GBP 2.61B 377M Dec/2025
Glaxosmithkline GBP 3.47B 461.37M Dec/2025
Incyte USD 121.18M 22.18M Dec/2025
Ionis Pharmaceuticals USD 8M 5.66M Dec/2025
Karyopharm Therapeutics USD 1.48M 35.95M Dec/2025
Neurocrine Biosciences USD 17.6M 246.4M Dec/2025
Novavax USD 22.1M 608K Dec/2025
PTC Therapeutics USD 16.3M 7.02M Dec/2025
Regeneron Pharmaceuticals USD 584.6M 63M Dec/2025
Roche Holding CHF 8.48B 4.61B Dec/2025
Sarepta Therapeutics USD 399.38M 247.93M Dec/2025
Ultragenyx Pharmaceutical USD 29M 1.01M Dec/2025
Vertex Pharmaceuticals USD 466M 51.2M Dec/2025